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Zusammenfassung
Hintergrund: Die paraneoplastische Hypoglykämie ist 
ein seltenes Syndrom im Zusammenhang mit Tumor-
erkrankungen. Sie ist häufig mit einer paraneoplasti-
schen Sekretion von «big»-Insulin-like Growth Factor-II 
(IGF-II) assoziiert. Methoden: Der vorliegende Fallbericht 
beschreibt das Syndrom bei einer 60-jährigen Patientin 
mit fortgeschrittenem Mammakarzinom 8 Jahre nach 
 Erstdiagnose. Ergebnisse und Schlussfolgerung: Die 
Nicht-Insellzelltumor-induzierte paraneoplastische Hypo-
glykämie (NICTH) kann ein Hinweis auf einen bisher 
nicht diagnostizierten Tumorprogress sein. Die Diagno-
sestellung sowie die adäquate Akut- und Kausaltherapie 
gehören ins Repertoire des Onkologen.
Keywords
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Summary
Background: Paraneoplastic hypoglycemia is a rare syn-
drome amoung tumorous diseases. It is often associated 
with a paraneoplastic secretion of ‘big’ insulin-like 
growth factor-II. Methods: We describe this syndrome in 
a 60-year-old patient with advanced breast cancer 
8 years after primary diagnosis. Results and Conclusion: 
This non-islet cell tumor-induced hypoglycemia may be 
the only evidence for an otherwise clinically occult dis-
ease progression. Fast diagnosis and appropriate acute 
and causal treatment concepts should be part of onco-
logical management.
Introduction
Paraneoplastic hypoglycemia is a rare but severe complica-
tion in malignancies that was first described in 1930 by Doege 
in a case of mediastinal fibrosarcoma [1]. Since then, several 
cases of this adverse event have been described in combina-
tion with benign and malignant mesenchymal and epithelial 
neoplasms. The syndrome has only been described once in a 
patient with advanced breast cancer [2].
In most cases, hypoglycemia is due to a paraneoplastic se-
cretion of ‘big’ insulin-like growth factor-II (IGF-II) [3, 4], a 
partially processed precursor of IGF-II. This abnormal IGF-II 
forms smaller complexes with IGF-binding proteins (IGFBPs) 
[5–7], and consecutively shows increased permeability and a 
higher bio-availability. Therefore, most patients with tumor-
induced hypoglycemia exhibit IGF-II concentrations within 
normal ranges.
The production of IGF-I and IGFBP-3 is reduced as a con-
sequence of negative feedback induced by growth hormone 
(GH). This results in a higher concentration of free IGF-II, 
and in an elevated IGF-II to IGF-I ratio, which can be used as 
diagnostic tool for paraneoplastic hypoglycemia (reviewed in 
[8]).
This paraneoplasm is distinct from insulin-induced hypo-
glycemias (observed, for example, in insulinomas), and has 
been termed non-islet cell tumor-induced hypoglycemia 
(NICTH). Although this complication is very rare, especially 
in gynecological malignancies, it is a severe metabolic emer-
gency, potentially leading to hypoglycemic coma. Hence, a 
fast diagnosis and effective treatment are essential.
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Case Report
In June 2001, a 52-year-old woman presented with a mass in her left 
breast and involvement of the left axillary lymph nodes. The right side 
was unsuspicious. A core needle biopsy showed a moderately differenti-
ated ductulo-lobular breast cancer with positive hormone receptor status. 
Staging investigations, including x-ray of the chest, abdominal sono-
graphy and bone scintigraphy, demonstrated bone metastases, while the 
parenchymal organs were without pathological findings. The patient 
 received an aromatase inhibitor (anastrozole) and a bisphosphonate 
 (clodronate) as palliative treatment.
In March 2002, pleural and pulmonary metastases were diagnosed and 
chemotherapy with paclitaxel and mitoxantrone was initiated, leading to 
partial remission. In September 2002, the patient underwent breast con-
serving surgery of the left side with axillary lymph node sampling and 
mastopexy on the right side (stage: ypT3 ypN2 cM1 G2).
After surgery, the endocrine therapy was switched to letrozole and 
clodronate until July 2006. At this point, progression of bone metastases 
and recurrence of pleural metastases were detected, and therapy with ful-
vestrant and clodronate was initiated. Since July 2007, the patient has 
been given several therapy regimens, including capecitabine followed by 
exemestane, liposomal doxorubicin and docetaxel, resulting in partial re-
mission. The remaining pulmonary metastases were treated by palliative 
radiation until July 2009. Maintenance therapy with anastrozole was then 
started and switched to letrozole because of negative side effects. The 
 patient subsequently developed skin metastases on her back and anti-
hormonal therapy with fulvestrant was re-initiated in August 2009.
In October 2009, the patient was admitted to our clinic in a pre-coma-
tose state. Laboratory analysis showed a severe hypoglycemia with a 
plasma-glucose level of 9 mg/dl. Administration of glucose promptly ame-
liorated the patient’s state. She regained consciousness, was fully orien-
tated and did not present with any neurological deficiencies. To rule out 
intracranial sources of her loss of consciousness, a cranial CT (computed 
tomography) was performed. The scan did not reveal signs of intracranial 
bleeding or brain metastases.
Further laboratory testing exhibited significantly decreased levels of 
IGF-I, IGFBP-3, insulin and C-peptide, whereas IGF-II levels were low 
but within the normal range (table 1). This led to a pathological IGF-II to 
IGF-I ratio of >> 14 (normal: < 0 [2]) and a suspected diagnosis of a para-
neoplastic hypoglycemia. Further investigations, including ultrasound of 
the liver and blood tumor marker (CA 15–3 > 3,000 kU/l, normal range 
< 25 kU/l), were carried out and showed a massive hepatic progression, 
thereby substantiating our hypothesis. Under symptomatic treatment 
with constant infusion of glucose (20%, 100 ml/h), dexamethasone (4 mg/
day) and somatostatine (100 µg/day), the patient was without symptoms 
for several days.
The only known effective treatment of paraneoplastic hypoglycemia is 
the reduction of tumor mass. In this case of disseminated breast cancer, 
surgical treatment was not indicated so that we planned another palliative 
chemotherapy. To our regret, patient’s state worsened due to the massive 
progression and she died 11 days after referral.
Discussion
Although breast cancer is the most common malignancy in 
women in the western hemisphere, paraneoplastic hypoglyce-
mia is a very rare syndrome in breast cancer and gynecologi-
cal oncology [2, 9–11]. Until now only 8 cases have been re-
ported in the scientific literature, and to the best of our 
knowledge this is the second report on an NICTH in a breast 
cancer patient [2] (see table 2).
Hypoglycemia is a well-known emergency in clinical rou-
tine, mostly due to diabetes medication. As a complication in 
malignancies, it is commonly described as overproduction of 
insulin (by insulinomas or ectopic insulin-producing tumors) 
or as being caused by hepatic or adrenal cancerous destruc-
tion. Paraneoplastic hypoglycemia is usually induced by a 
huge tumor mass either of a primary tumor or an advanced 
malignancy. Therefore, paraneoplastic hypoglycemia could be 
the first manifestation of tumor progression or lead to the pri-
mary diagnosis of a so-far unknown neoplasm.
NICTH is typically caused by an inadequate production of 
insulin or IGF and IGFBPs. Ectopic secretion of an incom-
pletely processed IGF-II by the tumor (‘big’ IGF-II) acts as 
an IGF with high bio-availability for IGF and insulin recep-
tors and causes hypoglycemia [12]. In NICTH, insulin secre-
tion is suppressed, resulting in low insulin and C-peptide 
 levels. As negative feedback, high IGF activity restrains GH 
secretion, leading to reduced IGF-I and IGFBP-3 production 
in the liver [13], as shown in the presented patient (table 1).
Intravenous glucose administration is the essential treat-
ment for severe and persistent hypoglycemia. Hoff et al. [14] 
described infusion of glucagon as another treatment option. 
Application of glucocorticoids seems to be promising by cor-
recting the GH-IGF axis, stimulating gluconeogenesis and,  in 
some cases, suppressing the production of ‘big’ IGF-II. More-
over, glucocorticoids, GH or combination thereof could also 
inhibit NICTH and reduce associated symptoms [15]. The use 
of somatostatine analogues is a controversial issue. Chung et 
Table 1. Overview of all relevant laboratory analysis at admission of the 
patient according to their reference parameters
Parameter Value Reference range
Glucose, mg/dl 9 55–115
CA15–3, kU/l > 3000 < 25
Insulin, mU/ 5.4l 6–29.1
Peptide-C, µg/l << 0.1 0.9–7.1
HbA1c, % 4.91 4.8–6.0
IGF-I, µg/l << 25.0 81–225
IGF-BP3, mg/l << 0.5 3.4–6.9
IGF-II, ng/ml 372 370–900
Hb = hemoglobin, IGF = insulin-like growth factor, 
BP = binding protein
Table 2. Summary of all cases of NICTH in gynecological disease 
published in international journals
Tumor entities with NICTH Reference Number of cases
Phyllodes tumor of the breast
Unknown status [18, 19] 2
Benign [20, 21] 2
Malignant [22] 1
Metastasized breast cancer [2] 1
Fibrous tumor of the uterus [23] 1
Ovarian cancer [24] 1
NICTH = non-islet cell tumor-induced hypoglycemia
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al. [16] observed a reduction of ‘big’ IGF-II secretion evoked 
by continuous somatostatine infusion. Another author re-
ported that octreotid did not restore glucose levels [17].
Removal or cytotoxic reduction of the ‘big’ IGF-II-produc-
ing tumor is the only causal therapy. Through an increase in 
individualized therapeutic options (e.g. small molecules, anti-
bodies) the survival of patients in advanced tumor stages will 
improve. Therefore, diagnosis and treatment of this oncologi-
cal emergency case may be more common in future.
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